Novo Nordisk A/S $NVO Shares Sold by Webster Bank N. A.

Webster Bank N. A. cut its stake in Novo Nordisk A/S (NYSE:NVO) by 81.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,460 shares of the company’s stock after selling 24,246 shares during the quarter. Webster Bank N. A.’s holdings in Novo Nordisk A/S were worth $303,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of NVO. Nisa Investment Advisors LLC lifted its position in Novo Nordisk A/S by 41.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,700 shares of the company’s stock worth $94,000 after acquiring an additional 500 shares in the last quarter. Harrell Investment Partners LLC grew its position in Novo Nordisk A/S by 5.8% in the third quarter. Harrell Investment Partners LLC now owns 14,167 shares of the company’s stock valued at $786,000 after acquiring an additional 775 shares in the last quarter. Oak Family Advisors LLC raised its stake in shares of Novo Nordisk A/S by 8.3% during the third quarter. Oak Family Advisors LLC now owns 153,085 shares of the company’s stock valued at $8,495,000 after purchasing an additional 11,705 shares during the period. Argonautica Private Wealth Management Inc. raised its stake in shares of Novo Nordisk A/S by 6.9% during the third quarter. Argonautica Private Wealth Management Inc. now owns 8,671 shares of the company’s stock valued at $481,000 after purchasing an additional 559 shares during the period. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in shares of Novo Nordisk A/S during the third quarter worth $39,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 2.6%

NYSE:NVO opened at $58.85 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The company has a market capitalization of $262.78 billion, a price-to-earnings ratio of 17.11 and a beta of 0.66. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $93.80. The stock has a 50-day simple moving average of $49.65 and a 200 day simple moving average of $55.40.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.25. The firm had revenue of $11.79 billion for the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Amazon Pharmacy began offering Novo Nordisk’s new Wegovy pill through insurance plans and a cash-pay option, expanding U.S. distribution and making the first-ever oral GLP‑1 from Novo more accessible to patients — a direct demand and revenue catalyst. Amazon Pharmacy offers Novo Nordisk’s Wegovy pill
• Positive Sentiment: Major retail pharmacy availability reported by CNBC/MSN increases distribution visibility and could shorten the time to volume adoption for the Wegovy pill, supporting revenue upside versus slower clinic-based rollouts. Amazon Pharmacy starts offering Novo Nordisk’s Wegovy weight-loss pill
• Positive Sentiment: Investor research pieces flag Novo as a top pick for 2026 and highlight the FDA‑approved Wegovy pill as a growth catalyst; analysts note robust margins and free cash flow potential (but also cite pricing and competition risks). This supportive analyst tone can lift sentiment and trading interest. Novo Nordisk: A Pill For Growth
• Neutral Sentiment: The JPMorgan Healthcare Conference will put pharma pipeline updates and potential M&A back in focus; Novo may benefit from heightened investor attention but concrete impacts depend on announcements made at the event. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Marketing and PR activities — e.g., a public conversation on weight stigma at a major NYC commuter hub — help brand and patient engagement but are unlikely to move near-term revenue materially. Novo Nordisk conducts a new conversation on weight stigma at major NYC commuter hub
• Neutral Sentiment: Recent price commentary (Zacks note on a modest prior-day gain) reflects momentum but is informational rather than a fundamental driver. Novo Nordisk (NVO) Surpasses Market Returns

Analyst Ratings Changes

A number of equities research analysts recently weighed in on NVO shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, December 29th. Jefferies Financial Group started coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They issued an “underperform” rating for the company. Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Tuesday, December 23rd. Finally, Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have issued a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $56.21.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.